Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...

H.C. Wainwright analyst Mitchell Kapoor says that amid “impressive” low-dose efficacy data, Neurogene’s (NGNE) NGN-401 led to a treatment-related severe adverse event in a single high-dose patient, ...

BMO Capital lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 and keeps an Outperform rating on the shares. The shares are ...

Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...

Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...

At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.

Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.